DNA methylation signature as a biomarker of major neuropsychiatric disorders

Shirvani Farsani, Zeinab; Maloum, Zahra; Bagheri Hosseinabadi, Zahra; Vilor Tejedor, Natàlia, 1988-; Sadeghi, Iman

doi:http://dx.doi.org/10.1016/j.jpsychires.2021.06.013

DNA methylation signature as a biomarker of major neuropsychiatric disorders

Citation

Shirvani-Farsani Z, Maloum Z, Bagheri-Hosseinabadi Z, Vilor-Tejedor N, Sadeghi I. DNA methylation signature as a biomarker of major neuropsychiatric disorders. J Psychiatr Res. 2021;141:34-49. DOI: 10.1016/j.jpsychires.2021.06.013

Abstract

DNA methylation is a broadly-investigated epigenetic modification that has been considered as a heritable and reversible change. Previous findings have indicated that DNA methylation regulates gene expression in the central nervous system (CNS). Also, disturbance of DNA methylation patterns has been associated with destructive consequences that lead to human brain diseases such as neuropsychiatric disorders (NPDs). In this review, we comprehensively discuss the mechanism and function of DNA methylation and its most recent associations with the pathology of NPDs-including major depressive disorder (MDD), schizophrenia (SZ), autism spectrum disorder (ASD), bipolar disorder (BD), and attention/deficit hyperactivity disorder (ADHD). We also discuss how heterogeneous findings demand further investigations. Finally, based on the recent studies we conclude that DNA methylation status may have implications in clinical diagnostics and therapeutics as a potential epigenetic biomarker of NPDs.